For the quarter ending 2025-09-30, APGE had -$16,572K decrease in cash & cash equivalents over the period. -$54,255K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -65,021 | -121,435 |
| Depreciation expense | 406 | 606 |
| Equity-based compensation expense | 11,877 | 22,470 |
| Amortization of discounts on marketable securities | 1,620 | 4,139 |
| Non-cash lease expense | 940 | 1,778 |
| Prepaid expenses and other current assets | 2,106 | 1,642 |
| Other non-current assets | 181 | 8,359 |
| Accounts payable | -5,302 | 4,607 |
| Operating lease liability | -992 | -1,985 |
| Accrued expenses | 7,744 | -2,407 |
| Net cash used in operating activities | -54,255 | -110,506 |
| Purchases of marketable securities | 107,632 | 145,580 |
| Maturities of marketable securities | 125,577 | 241,772 |
| Purchases of property and equipment | 0 | 5,085 |
| Net cash provided by (used in) investing activities | 17,945 | 91,107 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock under the atm, net of issuance costs | 19,382 | - |
| Proceeds from exercise of options and employee stock purchase plan purchases | 356 | 1,802 |
| Net cash provided by financing activities | 19,738 | 1,802 |
| (decrease) increase in cash, cash equivalents and restricted cash | -16,572 | -17,597 |
| Cash and cash equivalents at beginning of period | 142,083 | - |
| Cash and cash equivalents at end of period | 107,914 | - |
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)